A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Participants With Elevated Serum Lipoprotein(a)

An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Subjects With Elevated Serum Lipoprotein(a)

The main objective of this study is to evaluate the pharmacokinetics (PK) of a single dose of Olpasiran in Chinese participants with elevated serum lipoprotein(a) (Lp[a]).

Study Overview

• Status: Completed
• Conditions: Elevated Serum Lipoprotein(a)
• Intervention / Treatment: Drug: Olpasiran

• Study Type: Interventional
• Enrollment (Actual): 24
• Phase: Phase 1

Contacts and Locations

Study Locations

• Hong Kong
  • HK
    • Hong Kong, HK, Hong Kong
      • Queen Mary Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

Inclusion eligibility criteria will be evaluated in 2 parts during the screening period:

• Part 1: After written informed consent is obtained, subjects will provide a blood sample for a preliminary Lp(a) assessment to determine eligibility for Part 2 screening. Subjects with Lp(a) ≥ 70 nmol/L (or approximately ≥ 27 mg/dL) will be eligible to return to the CRU Part 2 screening. Subjects not eligible to return for Part 2 screening will be screen failed.
• Part 2: Eligible subjects will complete all remaining screening procedures and tests that establish eligibility within 40 days prior to the Day 1 visit.

Part 1:

• Must be a resident in mainland China, Hong Kong, or Taiwan, and of Chinese Ancestry.
• Male or female subjects, between 18 and 60 years of age (inclusive) at the time of Screening.
• Screening serum Lp(a) ≥ 70 nmol/L (or approximately ≥ 27 mg/dL).

Part 2:

• In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, vital sign measurements, and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia [e.g., suspicion of Gilbert's syndrome based on total and direct bilirubin] is not acceptable) as assessed by the Investigator (or designee).
• Body mass index between 18 and 32 kg/m^2 (inclusive) at the time of Screening.
• Subjects who are on statin must be on a stable dose of the same statin for at least 6 weeks prior to enrollment, and plan to remain on a stable dose (i.e., no change in medication or dosage) for the duration of the study.

• Females must be of non-reproductive potential:

  a. Postmenopausal defined as: i. Age of ≥ 55 years with no menses for at least 12 months; OR ii. Age of < 55 years with no menses for at least 12 months AND with a follicle stimulating hormone (FSH) level > 40 IU/L or according to the definition of "postmenopausal range" for the laboratory involved; OR b. History of hysterectomy; OR c. History of bilateral oophorectomy.

Exclusion Criteria:

• History or clinical evidence of peripheral neuropathy.
• Currently receiving apheresis as lipid reducing therapy.
• History or clinical evidence of bleeding diathesis or any coagulation disorder, including prothrombin time (PT), activated partial thromboplastin time (APTT), or platelet count outside of the laboratory's normal reference range at screening. Subjects with PT and/or APTT values that are outside of the laboratory's normal reference range at screening may still be eligible to proceed to enrollment if the results are judged by the investigator in consultation with the study medical monitor to not be clinically significant.
• History or clinical evidence of diabetes mellitus, including a fasting glucose ≥ 125 mg/dL (6.9 mmol/L) at Screening.
• Use of any herbal medicines, vitamins or dietary supplements known to affect lipid metabolism (e.g. sigh oils > 100mg/day, red yeast extract), within 30 days prior to dosing on Day 1 and for the duration of the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Olpasiran Dose A; Participants will be administered Olpasiran dose A as a subcutaneous injection.	Drug: Olpasiran; Subcutaneous injection; Other Names: AMG 890
Experimental: Olpasiran Dose B; Participants will be administered Olpasiran dose B as a subcutaneous injection.	Drug: Olpasiran; Subcutaneous injection; Other Names: AMG 890

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum Observed Concentration (Cmax) of Olpasiran	The serum pharmacokinetic (PK) parameters of olpasiran were calculated using standard noncompartmental methods.	Predose, 30 and 60 minutes, 2, 3, 6, 9, 12, 24, and 36 hours postdose on Day 1 and on study Days 3, 4, 7, 15, 29, 57, and 85

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Area Under the Serum Concentration-time Curve From Time 0 Extrapolated to Infinity (AUCinf) of Olpasiran	The serum PK parameters of olpasiran were calculated using standard noncompartmental methods.	Predose, 30 and 60 minutes, 2, 3, 6, 9, 12, 24, and 36 hours postdose on Day 1 and on study Days 3, 4, 7, 15, 29, 57, and 85
Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Olpasiran	The serum PK parameters of olpasiran were calculated using standard noncompartmental methods.	Predose, 30 and 60 minutes, 2, 3, 6, 9, 12, 24, and 36 hours postdose on Day 1 and on study Days 3, 4, 7, 15, 29, 57, and 85
Time to Cmax (Tmax) of Olpasiran	The serum PK parameters of olpasiran were calculated using standard noncompartmental methods.	Predose, 30 and 60 minutes, 2, 3, 6, 9, 12, 24, and 36 hours postdose on Day 1 and on study Days 3, 4, 7, 15, 29, 57, and 85
Apparent Terminal Elimination Half-life (T1/2) of Olpasiran	The serum PK parameters of olpasiran were calculated using standard noncompartmental methods.	Predose, 30 and 60 minutes, 2, 3, 6, 9, 12, 24, and 36 hours postdose on Day 1 and on study Days 3, 4, 7, 15, 29, 57, and 85
Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of Olpasiran	The serum PK parameters of olpasiran were calculated using standard noncompartmental methods.	Predose, 30 and 60 minutes, 2, 3, 6, 9, 12, 24, and 36 hours postdose on Day 1 and on study Days 3, 4, 7, 15, 29, 57, and 85
Apparent Total Body Clearance (CL/F) of Olpasiran	The serum PK parameters of olpasiran were calculated using standard noncompartmental methods.	Predose, 30 and 60 minutes, 2, 3, 6, 9, 12, 24, and 36 hours postdose on Day 1 and on study Days 3, 4, 7, 15, 29, 57, and 85
Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)	An adverse event (AE) was defined as any untoward medical occurrence in a clinical trial participant. A TEAE was defined as an AE that starts on or after the first dose of investigational product and up to end of study. Clinically significant changes in clinical laboratory tests, 12-lead electrocardiograms, and vital signs were reported as AEs.	Up to Day 225
Percentage Change From Baseline in Triglycerides	Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.	Baseline and Days 7, 15, 57, 155 and 225
Percentage Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C)	Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.	Baseline and Days 7, 15, 57, 155 and 225
Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)	Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.	Baseline and Days 7, 15, 57, 155 and 225
Percentage Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)	Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.	Baseline and Days 7, 15, 57, 155 and 225
Percentage Change From Baseline in Total Cholesterol	Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.	Baseline and Days 7, 15, 57, 155 and 225
Percentage Change From Baseline in Apolipoprotein A1 (ApoA1)	Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.	Baseline and Days 7, 15, 57, 155 and 225
Percentage Change From Baseline in Apolipoprotein B (Apo B)	Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.	Baseline and Days 7, 15, 57, 155 and 225
Percentage Change From Baseline in Lipoprotein-a (Lp[a])	Participants were fasted overnight (at least 10 hours) before collection of blood samples for lipids.	Baseline and Days 2, 4, 7, 15, 29, 57, 85, 113, 155, 183 and 225

Collaborators and Investigators

• Sponsor: Amgen
• Investigators: Study Director: MD, Amgen

Publications and helpful links

Helpful Links

• AmgenTrials clinical trials website

Study record dates

Study Major Dates

• Study Start (Actual): July 28, 2021
• Primary Completion (Actual): November 12, 2021
• Study Completion (Actual): March 18, 2022

Study Registration Dates

• First Submitted: July 26, 2021
• First Submitted That Met QC Criteria: July 26, 2021
• First Posted (Actual): August 3, 2021

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: January 20, 2025
• Last Verified: January 1, 2025

More Information

Terms related to this study

• Keywords: Olpasiran; Elevated serum lipoprotein(a)
• Other Study ID Numbers: 20190095

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
• IPD Sharing Time Frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
• IPD Sharing Access Criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No